Register for a live broadcast to learn more about TRODELVY (sacituzumab govitecan-hziy) with Dr. Hope S. Rugo

General Discussions

PD-L1 Immune Cell Expression Critical to Atezolizumab Efficacy in TNBC

By Wayne Kuznar
Improvements observed in progression-free survival (PFS) and overall survival (OS) with the addition of first-line atezolizumab (Tecentriq) to nab-paclitaxel (Abraxane) in patients with metastatic triple-negative breast cancer (TNBC) or inoperable locally advanced TNBC are exclusive to those patients with PD-L1 expression ≥1% in immune cells, according to a biomarker subgroup analysis of the phase III IMpassion130 study.1

Exploratory analyses of other biomarkers that included PD-L1 expression on tumor cells, intratumoral CD8+ T cells, stromal tumor-infiltrating lymphocytes, and BRCA1/2 mutation status, confirmed the importance of PD-L1 expression on immune cells in predicting clinical benefit derived from atezolizumab and nab-paclitaxel, said study co-author Leisha A. Emens, MD, PhD. She presented the data at the 2018 San Antonio Breast Cancer Symposium (SABCS).

“PD-L1 expression on tumor cells did not provide additional information beyond PD-L1 immune cell status,” said Emens, professor of medicine in hematology/oncology and co-leader of the Hillman Cancer Immunology and Immunotherapy Program at the University of Pittsburgh Medical Center. “PD-L1 immune cell expression was the best predictor of clinical benefit as the patient subgroups with tumor-infiltrating immune cells or cytotoxic T cells derived clinical benefit with atezolizumab plus nab-paclitaxel if their tumors were also PD-L1 immune cell-positive. PFS and OS results were consistent regardless of BRCA1/2 mutation status.”

The data support the routine testing for PD-L1 immune cell status to determine whether patients might benefit from atezolizumab plus nab-paclitaxel, she added.

PD-L1 in the IMpassion130 patient population was expressed primarily on tumor-infiltrating immune cells (41%). Twenty-seven percent had low levels at 1% to <5%, and 14% had levels in their immune cells at ≥5%. In contrast, only 9% of study had PD-L1 expression on tumor cells. Most of the patients with PD-L1 expression on tumor cells also had PD-L1 expression on their immune cells, Emens noted, with only 2% having PD-L1 expression exclusively on tumor cells.

Among the subgroup with PD-L1–negative immune cells, as first reported here, the median PFS was 5.6 months in both treatment arms (HR, 0.94; 95% CI, 0.78-1.13; P = .5152).

The interaction between PD-L1 immune cell status and the difference in PFS between treatment arms was significant (P = .0055).

A similar association was detected between PD-L1 status and OS in the subgroup with PD-L1-positive immune cells. The median OS was 25.0 months in the arm assigned to atezolizumab and nab-paclitaxel compared with 15.5 months in those assigned to placebo and nab-paclitaxel (HR, 0.62; 95% CI, 0.45-0.86; P = .0035). There was no treatment effect observed in the PD-L1 immune cell-negative subpopulation, with a median OS of 18.9 months and 18.4 months, respectively (HR, 1.02; 95% CI, 0.79-1.31; P = .9068).

The test for interaction between PD-L1 immune cell status and difference in OS between the treatment arm was significant (P = .0178).

There were trends toward associations between PD-L1 immune cell positivity and worse PFS and OS.

 “Taken together, these data definitively show that PD-L1 immune cell positivity is predictive of both PFS and OS benefit with atezolizumab and nab-paclitaxel,” Emens said.

The benefit to the combination on PFS and OS was significant in patients with low and high levels of PD-L1 expression on their immune cells. This suggests that an expression level of 1% may represent a threshold for identifying those benefits who are likely to benefit clinically from this combination,” Emens said.

IMpassion130 evaluated atezolizumab plus chemotherapy versus placebo and nab-paclitaxel in treatment-naïve patients with metastatic TNBC. Patients were randomized 1:1 to receive nab-paclitaxel at 100 mg/m2 intravenously on days 1, 8, and 15 of the 28-day cycle with atezolizumab at 840 mg intravenously (n = 451) on days 1 and 15 of a 28-day cycle or with placebo (n = 451). Treatment was given until disease progression or unacceptable toxicity.

The coprimary endpoints were PFS and OS in both the ITT and PD-L1–positive populations. PD-L1 expression was defined as positive if expression was at least 1% on tumor-infiltrating immune cells.

Other biomarker analyses performed in IMPassion130 were outcomes according to intratumoral CD8+ T cells by immunohistochemistry and stromal tumor-infiltrating lymphocytes by H&E, and BRCA1/2 mutation status.

“Pre-existing immune biology has been associated with clinical benefit from other agents that target the PD-1 pathway in other cancer types,” Emens said. “So, in these exploratory analyses, we sought to evaluate whether this immune biology as well as the BRCA1/2 mutation status were associated with clinical benefit from atezolizumab with nab-paclitaxel.”

Among patients with CD8+ T cells in their tumors, benefit on PFS and OS was observed only if their tumors were also PD-L1 immune cell-positive. The HRs in this group were 0.33 (95% CI, 0.13-0.67; P = .03) for PFS and 0.25 (95% CI, 0.06-1.02; P = .05) for OS with combination therapy.

In contrast, the HRs in patients with CD8+ tumors but PD-L1 immune cell negativity were 0.89 (95% CI, 0.66-1.20; P = .45) for PFS and 0.77 (95% CI, 0.50-1.17; P = .21) for OS. Among the 280 patients who were positive for both CD8+ expression and PD-L1 immune cell expression, significant benefit was derived from the combination for both PFS (HR, 0.61; 95% CI, 0.46-0.80; P £.005) and OS (HR, 0.55; 95% CI, 0.38-0.80; P ≤ 005).

Similarly, PD-L1 immune cell-negative patients whose tumors had stromal TILs derived no clinical benefit from the addition atezolizumab—the HR for PFS was 0.99 (95% CI, 0.62-1.57; P = .97) and the HR for OS was 1.53 (95% CI, 0.76-3.08; P = .24). In contrast, patients whose tumors contained stromal TILs and expressed PD-L1 on immune cells had a significant improvement in PFS (HR 0.53; 95% CI, 0.38-0.74; P ≤.005) and OS (HR 0.57; 95% CI, 0.35-0.92; P = .02) with the chemoimmunotherapy.

Of patients evaluable for BRCA mutation status, 15 had BRCA1/2 mutant tumors. These patients had a significant improvement in PFS with chemoimmunotherapy only if their tumors were also PD-L1 immune cell-positive (HR, 0.45; 95% CI, 0.21-0.96; P = .04). Investigators also observed a trend toward improvement in OS (HR 0.87; 95% CI, 0.26-2.85; P = .82).

“I would note that these data are somewhat limited by the small patient numbers,” Emens said. “However, they do show that mutations in BRCA- and PD-L–expressing immune cells are independent biomarkers, and patients with BRCA1 or -2 mutated tumors derived clinical benefit only if their tumors were also PD-L1 immune cell-positive.”

In the primary analysis, as presented previously, atezolizumab plus nab-paclitaxel resulted in a statistically significant PFS benefit in the intent-to-treat (ITT) population compared with placebo plus nab-paclitaxel (HR, 0.80; 95% CI, 0.69-0.92; P = .0025) and a trend toward improved OS (HR, 0.84; 95% CI, 0.69-1.02; P = .0840).2

Among patients with PD-L1–positive tumors, both PFS (HR, 0.62; 95% CI, 0.49-0.78; P <.001) and OS (HR, 0.62; 95% CI, 0.45-0.86) were clinically meaningful with the addition of atezolizumab.

In the PD-L1 immune cell-positive subpopulation, the median PFS was 7.5 months in patients randomized to the atezolizumab-nab-paclitaxel combination compared with 5.0 months in patients assigned to placebo plus nab-paclitaxel (HR, 0.62; P <.0001).


  1. Emens LA, Loi S, Rugo HS, et al. IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer. In: Proceedings from the 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. Abstract GS1-04.
  2. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;3 79:2108-21.
This article originally appeared on OncLive® as “PD-L1 Immune Cell Expression Critical to Atezolizumab Efficacy in TNBC.”
Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.